


**In the Claims:**

This listing of claims will replace all prior versions, and listings, or claims in the application:

1-30. (Canceled)

31. (Currently Amended) A compound having the following structure:



wherein:

R<sub>1</sub> is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, and naphthyl ~~hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;~~

R<sub>2</sub> and R<sub>2</sub>' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; provided that R<sub>2</sub> and R<sub>2</sub>' are different;

R<sub>4</sub> is chosen from substituted benzyl, heterocyclyl and R<sub>16</sub>-alkylene-;

R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;


R<sub>16</sub> is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl;

wherein the stereogenic center to which R<sub>2</sub> and R<sub>2</sub>' are attached is of the R configuration and wherein said compound has a chiral purity of >95%.

or a pharmaceutically acceptable salt thereof.

32-49. (Canceled)

50. (Currently Amended) A compound having the following structure:



wherein:

~~R<sub>1</sub> is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, and naphthyl chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted benzyl, phenyl, naphthyl and substituted phenyl;~~

R<sub>2</sub> is chosen from lower alkyl and substituted lower alkyl and R<sub>2</sub>' is hydrogen;

R<sub>4</sub> is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; substituted benzyl, heterocyclyl, heteroaryl methyl; heteroarylethyl; heteroarylpropyl and R<sub>16</sub>-alkylene-, wherein R<sub>16</sub> is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl;


R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;

wherein the stereogenic center to which R<sub>2</sub> and R<sub>2</sub>' are attached is of the R configuration and wherein said compound has a chiral purity of >95%.

or a pharmaceutically acceptable salt thereof.

51-59. (Canceled)

60. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the following structure:



wherein:

R<sub>1</sub> is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;

R<sub>2</sub> and R<sub>2</sub>' are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl; provided that R<sub>2</sub> and R<sub>2</sub>' are different;

R<sub>4</sub> is chosen from substituted benzyl, heterocyclyl and R<sub>16</sub>-alkylene-;

R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;

R<sub>16</sub> is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl;


wherein the stereogenic center to which R<sub>2</sub> and R<sub>2</sub>' are attached is of the R configuration,

or a pharmaceutically acceptable salt thereof or salt of Claim 31.

61-63. (Canceled)

64. (Currently Amended) A pharmaceutical composition comprising a

pharmaceutically acceptable excipient and a compound or salt having the following structure:



wherein:

R<sub>1</sub> is chosen from hydrogen, lower alkyl, substituted lower alkyl, benzyl, substituted

benzyl, phenyl, naphthyl and substituted phenyl;

R<sub>2</sub> is chosen from lower alkyl and substituted lower alkyl and R<sub>2</sub>' is hydrogen;

R<sub>4</sub> is chosen from lower alkyl, cyclohexyl; phenyl substituted with hydroxy, lower alkoxy or lower alkyl; benzyl; substituted benzyl, heterocyclyl, heteroaryl methyl; heteroarylethyl; heteroarylpropyl and R<sub>16</sub>-alkylene-, wherein R<sub>16</sub> is di(lower alkyl)amino, (lower alkyl)amino, amino, lower alkoxy, or N-heterocyclyl;


R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;

wherein the stereogenic center to which R<sub>2</sub> and R<sub>2</sub>' are attached is of the R configuration,

or a pharmaceutically acceptable salt thereof of Claim 50.

65-67. (Canceled)

68. (Currently amended) A compound having the following structure:



wherein

~~R<sub>1</sub> is chosen from benzyl or halobenzyl lower alkyl, benzyl, substituted benzyl and substituted phenyl;~~

R<sub>2</sub> is hydrogen or lower alkyl;

R<sub>2</sub>' is hydrogen;

R<sub>4</sub> is R<sub>16</sub>-alkylene-;


R<sub>7</sub> is hydrogen, fluoro, chloro or methyl;

R<sub>5</sub>, R<sub>6</sub> and R<sub>8</sub> are hydrogen; and

R<sub>16</sub> is chosen from di(lower alkylamino), (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.

69. (Previously Presented) The compound according to claim 68, wherein the stereogenic center to which R<sub>2</sub> and R<sub>2</sub>' are attached is of the R configuration

70. (Currently Amended) A compound having the following structure:



wherein

$R_1$  is benzyl or halobenzyl ~~chosen from lower alkyl, benzyl, substituted benzyl and substituted phenyl;~~

$R_2$  is lower alkyl;

$R_2'$  is hydrogen;

$R_4$  is substituted benzyl, heterocyclyl, or  $R_{16}$ -alkylene-;


$R_6$  and  $R_7$  are chosen from hydrogen and halo;

$R_5$  and  $R_8$  are hydrogen; and

$R_{16}$  is chosen from di(lower alkyl)amino, (lower alkyl)amino, amino, pyrrolidinyl, piperidinyl, imidazolyl and morpholinyl.


71. (Previously Presented) The compound according to claim 70, wherein the stereogenic center to which  $R_2$  and  $R_2'$  are attached is of the R configuration.

72. (Previously Presented) A compound having the following structure:




73. (Previously Presented) The compound according to claim 72, wherein the chiral center is of the R configuration.

74. (Previously Presented) A compound having the following structure:



75. (Previously Presented) The compound according to claim 74, wherein the chiral center is of the R configuration.

76. (Previously Presented) A compound having the following structure:



77. (Previously Presented) The compound according to claim 76, wherein the chiral center is of the R configuration.